News

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against the myopia epidemic, which is expected to affect approximately 5 billion people worldwide by 2050.1

Space at the Euclid facility in Sterling, Virginia, has now been expanded over 40%. Additions include larger manufacturing space, quality assurance labs, offices, and engineering/R&D space.

“With the launch of our game-changing Euclid Max Ortho-K lens this year, we have entered a very exciting time at Euclid. But our steadfast commitment to innovation is not taking a break. We’ve just expanded our manufacturing space and employee resources for the second time in three years and continue to grow our leadership team for future expansion,” said Euclid Systems CEO, Joseph Boorady. “We’re pleased to welcome Greg Endicott and Mark Mercier, who bring decades of experience, innovation, and results in fast-paced healthcare environments. Their knowledge and leadership, as well as the brick-and-mortar expansion of our facilities, help fortify Euclid’s growth as a cutting-edge world leader in myopia management technologies.”

As Chief Information Officer (CIO), Greg Endicott will lead Euclid’s strategic technology program and drive business initiatives in collaboration with global business leaders, including exploration of emerging technologies and new strategies. Previously, Mr. Endicott had a leadership role at Baxter Bioscience and was inaugural CIO of two scientific research companies. New Senior Director of Operations is Mark Mercier, a transformation specialist with decades of experience in contact lens manufacturing at Bausch+Lomb. Mr. Mercier will drive efficient methodologies throughout Euclid’s manufacturing and fulfillment.

Additional information on Euclid’s state-of-the-art manufacturing facility, and what differentiates Euclid in the industry, may be viewed in the video presentation, “Euclid – Your Partner in Myopia Management”.

To learn more visit the link.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business